No Data
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
NeoGenomics (NEO) Upgraded to Buy: Here's Why
NeoGenomics Is Maintained at Neutral by B of A Securities
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Raises Target Price to $19
NeoGenomics Study Highlights CtDNA's Potential To Predict Recurrence In High-Risk Melanoma; RaDaR Sequencing Assay Identifies Molecular Residual Disease Across Broader Patient Range, Enabling Earlier Detection And Prognosis Monitoring
NeoGenomics' Newly Published Study Underscores Potential of CtDNA as a Predictive Tool for Monitoring Patients With High-Risk Melanoma
No Data
